Abstract 1191P
Background
Thyroid transcription factor-1 (TTF-1), is expressed in thyroid and lung tissue. TTF-1, assessed by immunohistochemistry (IHC), is a specific biomarker for lung adenocarcinoma, and is commonly used to confirm the pulmonary origin of neuroendocrine tumors (NET), as well. The majority of the available data suggest that TTF-1 is a favourable prognostic biomarker for lung adenocarcinomas, whereas its role in lung NET is controversial.
Methods
A multicenter retrospective study, including 155 Lung NET, all surgically removed, all with available IHC assessment for TTF-1.
Results
Median age was 59.5 years (13–86), N= 58 patients (37.4%) were males, N=40 (25.8%) were smokers, N=31 (20%) were atypical carcinoids, N=85 (54.8%) were centrally-located, N=89 (57.4%) were located in the right lung, N=4 patients (2.6%) presented a TNM stage IV at the diagnosis. Mitotic count was ≥2 per 10 high-power field (HPF) in N=35 cases (22.6%), necrosis was present in N=20 (12.9%). Grade 1 was reported in 103 cases (66.5%), whereas Ki-67 was >20% in N=5 (3.2%). TTF-1 was positive in 78 cases (50.3%), cromogranin A in 139 (89.7%) and synaptophysin in 137 (88.4%), respectively. The most common type of surgery was lobectomy in 91 patients (58.7%). Median overall survival (OS) was 46.9 months (0.6–323), median progression-free survival (PFS) was 39.1 months (0.6–323). Statistically significant associations were found between (i) TTF-1 positivity and female sex (p=0.007), and among (ii) TTF-1 positivity and the absence of necrosis (p=0.018). No other relevant associations were detected between TTF-1 and the remaining clinical or pathological variables.
Conclusions
This study highlights that TTF-1 positivity differs according to sex in lung NET patients, with a more common TTF-1 positive staining in female. Moreover, TTF-1 was associated with the absence of necrosis. These data suggest that TTF-1 could potentially represent a gender-related biomarker in this population. Further analyses are needed to establish the value of this observation, and to determine the value of TTF-1 as prognostic biomarker for lung NET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13